Advertisement
News
Advertisement

Royal Fornia Electronic Device Co., Ltd. Signs Technology Licensing Agreement to Integrate Masimo rainbow SET Pulse CO-Oximetry Into New Patient Monitors

Thu, 02/24/2011 - 3:37am
Bio-Medicine.Org

IRVINE, Calif. and GUANGDONG PROVINCE, China, Feb. 24, 2011 /PRNewswire/ -- Masimo (Nasdaq: MASI) and Royal Fornia Electronic Device Co., Ltd. jointly announce a worldwide technology licensing agreement to integrate Masimo rainbow SET® Pulse CO-Oximetry™ technology into Royal Fornia's new generation of multiparameter patient monitors—enabling advanced noninvasive blood constituent measurements that help clinicians to detect and treat life-threatening conditions earlier. Having recently received State Food and Drug Administration (SFDA) approval for Masimo rainbow® SET parameters in China, Royal Fornia establishes itself as one of the first domestic Chinese medical device manufacturers to commercially incorporate Masimo's breakthrough noninvasive blood constituent measurement capabilities.

Masimo rainbow® SET noninvasive and continuous measurements—like total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to the 'gold-standard' Measure-Through Motion and Low Perfusion performance of Masimo SET® oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR)—provide detailed physiological data that helps clinicians to more rapidly assess patients and detect adverse conditions much earlier.  With rainbow® SET measurements, the ability to noninvasively detect internal bleeding, carbon monoxide poisoning, methemoglobinemia, fluid responsiveness, low perfusion, desaturations, and abnormal pulse rates quickly, easily, and continuously

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading